Home › Companies › CATX

Perspective Therapeutics

Market cap $104M 120.8M shares (10-Q, Nov 4, 2026) × $0.860 close Nov 17, 2026

Most recent annual filing: 2026-03-15

Catalyst timeline

2 trackedQuarter catalyst calendar →
  1. Phase 3 pivotal NETs corporateyear-end 2026Phase 3 pivotal NETs corporate, year-end 2026, routine
  2. NANETS presentation corporate updatelate 2026NANETS presentation corporate update, late 2026, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (5 active programs)

Technology platforms

CB7-Adma · Stony Brook University

Cucurbit[7]uril-adamantane (CB7-Adma) pre-targeting platform licensed from Stony Brook University; two-step antibody-then-radionuclide delivery system targeting cancer-specific proteins; preclinical optimization underway

224Ra/212Pb generator

Proprietary 224Ra/212Pb generator platform used to manufacture clinical drug product candidates for radiopharmaceutical delivery via alpha-generating isotope 212Pb to cancer cells; supports regional finished drug product supply network for clinical and commercial operations.

212Pb Radiopharmaceutical Platform

End-to-end engineered alpha-emitting 212Pb-based radioligand therapy platform; structural chemistry optimization, theranostic approach, and direct-to-hospital regional isotope manufacturing; focus area: solid tumor oncology

Targets: SSTR2, MC1R, FAP-α, CCK2R

Capital (as filed)

Cash
$41.0M cash and cash equivalents · Sep 30, 2026 (10-Q)
Short-term investments
$161M Sep 30, 2026
Operating cash flow
−$31.4M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$202M cash, runway into 2028 per the update of Nov 12, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (22)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (22 calls)

Every verdict Biotech Distilled has published on Perspective Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Speculative buy speculative Perspective Therapeutics (CATX): Scientific Deep Dive for VMT-α-NET and Pipeline Products Insider buying, validated Lead-212 biology, and a differentiated kidney-sparing chelator make CATX a compelling speculative entry ahead of 2026 data readouts.
  2. Buy core UPDATE: Perspective Therapeutics (CATX) Drops an Alpha Hammer at ASCO-GI 85.7% ORR and zero Grade 3 renal toxicity at ASCO-GI validate the Alpha thesis and remove the 'Speculative' qualifier, making CATX a core buy.
  3. Buy core UPDATE: Why Did Perspective Therapeutics (CATX) Just Dropped 15% (And Why It Could Be Buying Opportunity)? The 15% drop on VMT01 monotherapy pause is an overreaction; the core VMT-α-NET Alpha thesis is untouched and the stock is more attractive at the lower price.
  4. Buy core UPDATE: Perspective Therapeutics (CATX) Just Cleared the Deck (And Smart Money Bought the Dip) The $175M raise backed by specialist biotech funds eliminates the financing overhang, leaving only execution risk and making this a high-conviction buy.
  5. Hold UPDATE: Perspective Therapeutics (CATX) - The Smart Money Stampede Continues Massive institutional accumulation by specialist biotech funds further validates the thesis; existing holders should avoid selling into institutional buying ahead of late 2026 data.
  6. Buy core UPDATE: The CATX Institutional Land Grab Continues Avidity Partners' 6M-share stake adds to the institutional land grab, shrinking the float and setting up an explosive move on positive clinical catalysts.
  7. Buy core UPDATE: Perspective Therapeutics (CATX) - The Next Catalyst is Here AACR Cohort 3 high-dose data is weeks away; institutional float lock-up and a firm catalyst date make the current setup compelling.
  8. Buy core UPDATE: Perspective Therapeutics (CATX) Dropped a Stealth De-Risking Clue Ahead of AACR DLT assessment cleared in 8 Cohort 3 patients quietly de-risks the high-dose safety question ahead of AACR, strengthening the buy case.
  9. Buy core UPDATE: Perspective Therapeutics (CATX) - CATX Drops AACR Data ORR regression to 43% is expected mean-reversion from a tiny sample; zero DLTs at 6.0 mCi and a pristine safety profile confirm the chelator thesis and keep the M&A case intact.
  10. Buy core UPDATE: Perspective Therapeutics (CATX) - Q1 Drops Three Quiet Tells Cohort 4's smarter front-loaded dosing, a fourth clinical asset (PSV594), and management telegraphing regulatory alignment compound the thesis despite post-AACR drift.
  11. Buy core UPDATE: Perspective Therapeutics (CATX) - The ASCO Preview Quietly Resurrects VMT01 A second VMT01 monotherapy responder, deepening NETs responses, and PSV359 dose escalation to 6.0 mCi extend the platform thesis ahead of ASCO posters.
  12. Buy core UPDATE: Perspective Therapeutics (CATX) - The Chemist Hands Off to the Oncology Operator Founder-chemist transitioning to advisor while a Merck KGaA oncology-development veteran takes the CSO seat signals a phase change from platform invention to registration execution.
  13. Buy core UPDATE: Perspective Therapeutics (CATX) - Europe Puts a Ten-Year Fence Around the Alpha EU orphan designation with up to 10 years of market exclusivity stacks on top of the patent moat and represents a third-party regulatory validation of the significant-benefit case over Lutathera.
  14. Buy core UPDATE: Perspective Therapeutics (CATX) - The Phase 3 Finally Has a Dose and a Date Phase 3 now has a defined cumulative dose (20 mCi), a cadence, and a year-end 2026 site-activation target, converting management's regulatory-engagement language into a concrete protocol.
  15. Buy core UPDATE: Perspective Therapeutics (CATX) - Lantheus Opens the Exit Door Lantheus filing an explicit exit menu for its 10% stake creates a supply overhang and weakens the M&A leg of the thesis, warranting patience on new entries rather than chasing strength.
  16. Buy core UPDATE: Perspective Therapeutics (CATX) - Merck Walks In the Door Lantheus Walked Out Of Merck's Keytruda supply deal for PSV359 validates the wholly-owned FAP-α asset but does not restore the M&A leg dented by Lantheus; the overhang persists and patience on new entries remains warranted.
  17. Hold UPDATE: Perspective Therapeutics (CATX) - The Trickle Became a Faucet Lantheus accelerating to 2.7M shares sold in 13 days including a 1.4M-share single session changes the overhang's character, making patience more valuable than adding ahead of a motivated seller still holding 8.7M shares.
  18. Hold UPDATE: Perspective Therapeutics (CATX) - The FAP Program Finds a Side Door FDA Fast Track for PSV359 in FAP-positive solitary fibrous tumors adds a rare-disease regulatory route but does not resolve the Lantheus overhang; holding through ESMO remains the stance.
  19. Watch UPDATE: Perspective Therapeutics (CATX) - The ESMO Haircut ESMO showed Cohort 2 ORR settling at 33%, two Grade 3 renal events breaking the clean-kidney streak, and Phase 3 slipping to 2027, weakening the efficacy differentiation case enough to downgrade to Watch List.
  20. Watch UPDATE: Perspective Therapeutics (CATX) - Narrowing the Net NANETS adds no new data beyond a post-hoc SSTR2-enriched subgroup and a 1Q 2027 EOP2 date; VMT01 melanoma shows activity at only one dose and BMS combination data is absent, keeping the Watch List stance.
  21. Watch UPDATE: Perspective Therapeutics (CATX) - $1.67 of Cash in an $0.86 Stock Q3 shows $201.7M cash and runway into 2028 easing near-term financing fears, but BMS terminating the VMT01 nivolumab collaboration and an undisclosed Phase 3 budget keep the Watch List stance.
  22. Watch UPDATE: Perspective Therapeutics (CATX) - Lantheus Leaves the Register Lantheus selling its final large block at $0.80 (below cash per share) and falling below the 5% reporting threshold removes most of the visible overhang but leaves the license option on VMT-α-NET unresolved and the Phase 3 budget still undisclosed.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (1 quote from 1 filing)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (46)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 11, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

10 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)